Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men

Zgliczyński, S; Ossowski, Marcin; Słowińska-Srzednicka, J; Brzezińska, Agnieszka; Zgliczyński, Wojciech; Soszyński, P; Chotkowska, E; Srzednicki, M.; Sadowski, Zygmunt

doi:10.1016/0021-9150(95)05673-4

Cited by 138 publications

(98 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study also shows that testosterone replacement therapy decreases total cholesterol in hypogonadal men, with no significant changes in HDL cholesterol. This is in agreement with two other studies which reported a similar effect of androgen supplementation on total and HDL cholesterol (38,39). Testosterone treatment has also been shown to reduce total cholesterol in hypogonadal men with coronary artery disease, even in patients already on statins (23).…”

Section: Discussionsupporting

confidence: 92%

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

Kapoor

Goodwin²,

Channer³

et al. 2006

eur j endocrinol

690

621

View full text Add to dashboard Cite

Objective: Low levels of testosterone in men have been shown to be associated with type 2 diabetes, visceral adiposity, dyslipidaemia and metabolic syndrome. We investigated the effect of testosterone treatment on insulin resistance and glycaemic control in hypogonadal men with type 2 diabetes. Design: This was a double-blind placebo-controlled crossover study in 24 hypogonadal men (10 treated with insulin) over the age of 30 years with type 2 diabetes. Methods: Patients were treated with i.m. testosterone 200 mg every 2 weeks or placebo for 3 months in random order, followed by a washout period of 1 month before the alternate treatment phase. The primary outcomes were changes in fasting insulin sensitivity (as measured by homeostatic model index (HOMA) in those not on insulin), fasting blood glucose and glycated haemoglobin. The secondary outcomes were changes in body composition, fasting lipids and blood pressure. Statistical analysis was performed on the delta values, with the treatment effect of placebo compared against the treatment effect of testosterone.

show abstract

Section: Discussionsupporting

confidence: 92%

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

Kapoor

Goodwin²,

Channer³

et al. 2006

eur j endocrinol

690

621

View full text Add to dashboard Cite

show abstract

“…Intramuscular administration of T to hypogonadal or elderly men decreased total cholesterol and the atherogenic fraction of LDL cholesterol without significantly altering HDL cholesterol (34). In a more recent study, it was observed that men with coronary artery disease had significantly lower levels of androgens than controls, challenging the preconception that physiologically high levels of androgens in men account for their increased relative risk for coronary artery disease (9,10).…”

Section: Discussionmentioning

confidence: 99%

Testosterone inhibits early atherogenesis by conversion to estradiol: Critical role of aromatase

Nathan

Shi

Dinh

et al. 2001

Proc. Natl. Acad. Sci. U.S.A.

221

158

View full text Add to dashboard Cite

The effects of testosterone on early atherogenesis and the role of aromatase, an enzyme that converts testosterone to estrogens, were assessed in low density lipoprotein receptor-deficient male mice fed a Western diet. Castration of male mice increased the extent of fatty streak lesion formation in the aortic origin compared with testes-intact animals. Administration of anastrazole, a selective aromatase inhibitor, to testes-intact males increased lesion formation to the same extent as that observed with orchidectomized animals. Testosterone supplementation of orchidectomized animals reduced lesion formation when compared with orchidectomized animals receiving the placebo. This attenuating effect of testosterone was not observed when the animals were treated simultaneously with the aromatase inhibitor. The beneficial effects of testosterone on early atherogenesis were not explained by changes in lipid levels. Estradiol administration to orchidectomized males attenuated lesion formation to the same extent as testosterone administration. Aromatase was expressed in the aorta of these animals as assessed by reverse transcription-PCR and immunohistochemistry. These results indicate that testosterone attenuates early atherogenesis most likely by being converted to estrogens by the enzyme aromatase expressed in the vessel wall.atherosclerosis ͉ androgens ͉ anastrazole ͉ mice ͉ estrogen

show abstract

“…Similarly, over a 1-year period of testosterone replacement, HDL levels were reported to increase in men with MetS (Saad et al 2007), and in hypogonadal men over a shorter time period (Zitzmann & Nieschlag 2007). The majority of studies on the effect of testosterone on HDL-C, however, have generated contradictory results with either a decreases (Thompson et al 1989, Bagatell et al 1994 or no change (Zgliczynski et al 1996, Uyanik et al 1997, Boyanov et al 2003, Malkin et al 2004a, Kapoor et al 2006. The reasons for the differences between the studies are unclear; however, it has been proposed that testosterone stimulation of reverse cholesterol transport may lead to increased consumption of HDL-C (Wu & von Eckardstein 2003).…”

Section: Testosterone Effects On Lipidsmentioning

confidence: 99%

Testosterone: a metabolic hormone in health and disease

Kelly

Jones

2013

Journal of Endocrinology

396

319

View full text Add to dashboard Cite

Testosterone is a hormone that plays a key role in carbohydrate, fat and protein metabolism. It has been known for some time that testosterone has a major influence on body fat composition and muscle mass in the male. Testosterone deficiency is associated with an increased fat mass (in particular central adiposity), reduced insulin sensitivity, impaired glucose tolerance, elevated triglycerides and cholesterol and low HDL-cholesterol. All these factors are found in the metabolic syndrome (MetS) and type 2 diabetes, contributing to cardiovascular risk. Clinical trials demonstrate that testosterone replacement therapy improves the insulin resistance found in these conditions as well as glycaemic control and also reduces body fat mass, in particular truncal adiposity, cholesterol and triglycerides. The mechanisms by which testosterone acts on pathways to control metabolism are not fully clear. There is, however, an increasing body of evidence from animal, cell and clinical studies that testosterone at the molecular level controls the expression of important regulatory proteins involved in glycolysis, glycogen synthesis and lipid and cholesterol metabolism. The effects of testosterone differ in the major tissues involved in insulin action, which include liver, muscle and fat, suggesting a complex regulatory influence on metabolism. The cumulative effects of testosterone on these biochemical pathways would account for the overall benefit on insulin sensitivity observed in clinical trials. This review discusses the current knowledge of the metabolic actions of testosterone and how testosterone deficiency contributes to the clinical disease states of obesity, MetS and type 2 diabetes and the role of testosterone replacement.

show abstract

Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men

Cited by 138 publications

References 42 publications

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

Testosterone inhibits early atherogenesis by conversion to estradiol: Critical role of aromatase

Testosterone: a metabolic hormone in health and disease

Contact Info

Product

Resources

About